Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 25.95M P/E - EPS this Y - Ern Qtrly Grth -
Income -10.01M Forward P/E -1.51 EPS next Y - 50D Avg Chg 44.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -24.00%
Dividend N/A Price/Book 10.69 EPS next 5Y - 52W High Chg -84.00%
Recommedations 2.00 Quick Ratio 0.84 Shares Outstanding 7.92M 52W Low Chg 83.00%
Insider Own 17.91% ROA -115.51% Shares Float 9.56B Beta 0.97
Inst Own 1.61% ROE -1,281.43% Shares Shorted/Prior 575/5.95K Price 0.26
Gross Margin - Profit Margin - Avg. Volume 559,770 Target Price 80.00
Oper. Margin - Earnings Date Apr 29 Volume 916,728 Change -4.04%
About Akari Therapeutics Plc

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

Akari Therapeutics Plc News
04/15/24 Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
04/01/24 Akari Therapeutics Insider Ups Holding By 69% During Year
04/01/24 Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
03/05/24 Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
01/02/24 Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
12/14/23 Akari Therapeutics to Present at Biotech Showcase 2024
12/01/23 Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
11/16/23 Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
11/06/23 Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
10/03/23 Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
09/29/23 Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
09/27/23 Akari Therapeutics to Present at Emerging Growth Conference
09/21/23 Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
09/19/23 Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
09/05/23 Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
08/18/23 Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
08/15/23 Akari Therapeutics, Plc Announces ADS Ratio Change
08/02/23 Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
08/01/23 Here's Why Akari Therapeutics (NASDAQ:AKTX) Must Use Its Cash Wisely
07/27/23 Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation
AKTX Chatroom

User Image TigerZen Posted - 8 hours ago

$BDRX Come over to $AKTX She is ready to break out of this downward trend!

User Image TigerZen Posted - 8 hours ago

$AKTX Let's go! Need $5 from here!

User Image jennybaby Posted - 8 hours ago

$AKTX here is my either hopeful Or educated guess. The stock direction will be set higher/lower once it breaks out of this bizarre range, break $1.25-we move up $1.10 and God help us 🤯

User Image botnzer Posted - 1 day ago

$AKTX name one bio stock that came back from being down 99.9% from IPO.

User Image Slugmug Posted - 1 day ago

$SBFM would love to see this hit 2.50 at least in the next week if they drop a significant PR. Bought 2.12 first with small position, have worked it down to $1.35 avg. hate to say full position because it may form a base in the .80s and these are great levels to add. I do believe we see at least 40% from here in coming week. To beat down with so much money on hand and options for PRs to regain some traction. This is lowest of lows ever for this stock I believe accounting for r/s in past. I’m comfortable, but ready to take profits from here to $AKTX. It’s been beat down horribly, but has recently found a base in the $1.10-$1.20s area with an ind coming up. Look at how depressing board is but look at recent purchases and float is small. Also have pr about selling their product in china. This company uses a protein from tick saliva to treat for HSCT-TMA in children. Also they are developing treatments for GA and HSCT-TMA in adults. Their pediatric version has fast track approval. Go SBFM!

User Image ArrogantInvestor Posted - 3 days ago

$AKTX Averaged down here (as a hail mary)

User Image Brentney Posted - 4 days ago

$AKTX hey Akari, go fist yourself 🤜 You’re a complete and utter failure.

User Image botnzer Posted - 1 week ago

$AKTX went on vacation for a week and this went down! Shocker! lol. See you at zero. The death spiral of needing money to bring something to market. No conference presentation will save you only fda approval and a positive balance sheet. See you in pink stocks hell.

User Image hany1166 Posted - 1 week ago

$AKTX as i have presicted the dollar has printed bunch of F loser that bitch rachelle i hope u burn in hell

User Image MTN Posted - 1 week ago

$AKTX imagine a company so shit that the current price is $1.08, the bid is $1.11, and ask $1.25 and no one, and I mean no one is buying. That should tell you all you need to know about how they have run this into the ground.

User Image MTN Posted - 1 week ago

$AKTX wait for when it goers below $1. Then the real face of these assholes will show. Expecting a bankruptcy announcement any day now. How can anyone with a straight face say this will rebound?

User Image MTN Posted - 1 week ago

$AKTX down 60% in 3 months. Incredible.

User Image MTN Posted - 1 week ago

$AKTX for all you bulls, put your additional money where your mouth is....dump additional hundreds of thousands if you believe in these crooks. Go for it. Super cheap to buy in now.

User Image MTN Posted - 1 week ago

$AKTX continues to go down no matter the day, management continues to create 0 value for shareholders and should be sued.

User Image tonneke Posted - 1 week ago

$AKTX With all the complaining on this forum the price will not increase, just look at how many shares it is lowered and then it is just a joke, don't worry, it will be fine

User Image coachmc Posted - 1 week ago

$AKTX no, he’s asking the right questions that all longs who are honest with themselves should be asking since this has dropped >60 percent in one year without one peep from leadership. Give us your bullish assessment please

User Image BigBull005 Posted - 1 week ago

$AKTX Below 1 today

User Image systemish Posted - 1 week ago

$AKTX $NRXP Mr Sabby himself just outed himself I wonder what alias he uses on your board? SEC condemned naked shorter.

User Image tonneke Posted - 1 week ago

$AKTX haha the offer and the offer are quite apart

User Image dan16 Posted - 1 week ago

$AKTX Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 https://finance.yahoo.com/news/akari-therapeutics-present-pas-nomacopan-120000548.html

User Image MTN Posted - 1 week ago

$AKTX remind me of what else there is to look forward to here? They haven't gotten their voucher yet, no update on the CRADA, and they're merging with a pink sheets company with nothing going for it. Explain how this improves the bottom line, or even allows for a proper partnership. What this seems to me is another "refresh" to sucker in more investors.

User Image MTN Posted - 1 week ago

$AKTX guess the remaining hopium experts here are upset that truth is being told. Must be Ray's shadow accounts. The board, Rachelle and everyone else can get fucked.

User Image MTN Posted - 1 week ago

$AKTX 6+ years invested here, paid at one point $45 per share pre R/S. Wild to think most would accept even $5 now. What a joke and a scam this is.

User Image BGrateful Posted - 1 week ago

$AKTX I'm assuming this data will be actually released before ARVO. It is also my assumption, they are close to receiving their IND for GA if not already. Should move up once announced.

User Image Stock_Titan Posted - 1 week ago

$AKTX Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 https://www.stocktitan.net/news/AKTX/akari-therapeutics-to-present-pas-nomacopan-pre-clinical-6kitw7mpc67m.html

User Image MTN Posted - 1 week ago

$AKTX I wonder why so many of the remaining pumpers here are trying to pretend my posts don't exist 🤔 don't take it from me, just look at the chart.

User Image BGrateful Posted - 2 weeks ago

$AKTX

User Image BGrateful Posted - 2 weeks ago

$AKTX Does anyone think they could be going for a conditional approval in the EU for pediatric HSCT-TMA? Found it interesting that it was included in their annual report.

User Image MTN Posted - 2 weeks ago

$AKTX not worth even $1. Let it go bankrupt already.

User Image patatechaude Posted - 2 weeks ago

$AKTX My only green stock today.